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Aim of the study: The performed investigations aimed on the identiﬁcation of the anti-inﬂammatory
principal of extracts of leaves of Sambucus ebulus L. (dwarf elder) in order to rationalize the traditional
use of this plant for the treatment of chronically inﬂammatory diseases.
Materials and methods: Dwarf elder leaf extract was subjected to activity guided fractionation using
inhibition of TNF induced expression of vascular cell adhesion molecule 1 (VCAM-1) on the surface
of human umbilical vein endothelial cells (HUVECs) as monitoring tool (positive control: parthenolide
10M, VCAM-1 expression (% of control): 5.35±0.38%).
Results: Bio-guided isolation resulted in identiﬁcation of ursolic acid as anti-inﬂammatory principal.
Besides its inhibitory effects against TNF induced expression of VCAM-1 (IC50 6.25M), ursolic acidCAM-1
CAM-1
UVEC
NF-
nti-inﬂammatory activity
inhibits also TNF induced expression of ICAM-1 (IC50 value between 3.13 and 6.25M) (positive con-
trol: parthenolide 10M, ICAM-1 expression (% of control): 38.89±16.6%). Toxic effects of ursolic acid
on HUVECs can be drastically reduced using an enriched extract instead of the pure compound.
Conclusions: Our ﬁndings suggest an additional mechanism of the anti-inﬂammatory activity of ursolic
acid by demonstrating its ability to inhibit TNF-stimulated expression of VCAM-1 and ICAM-1 and
support the traditional use of extracts and preparations of Sambucus ebulus L., rich in ursolic acid, for the
inﬂamtreatment of chronically
. Introduction
Earliest written descriptions of the therapeutic use of dwarf
lder (Sambucus ebulus L.; Adoxacea) extracts in humans can be
ound in Pliny the Elder’s “Naturalis Historia” (23–79 A.D.) and
n “De Materia Medica” of Dioscorides (40–90 A.D.). In traditional
edicine, extracts from the root and leaves of Sambucus ebulus
. are frequently used for the treatment of inﬂammatory diseases
uch as inﬂammatory joint diseases, rheumatic pain and sore throat
Hiermann, 2007). Extracts of some aerial plant parts exhibited
istinct effects in the carrageenan induced rat paw edema assay
Ebrahimzadeh et al., 2006). Leave extracts showed also an impact
n the concentration of cytokines (interleukin-1, interleukin-
, TNF) when mixed with whole blood of healthy volunteers
Yesilada et al., 1997). Despite the traditional use of the leaves
f Sambucus ebulus L. especially in Mediterranean countries, up
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to now only one attempt was performed to identify the active
principle (Yesilada, 1997). An extract of the aerial plant parts was
subjected to activity guided isolation using different animal mod-
els (carrageenan or serotonin induced mice paw edema assays and
others) ending up with identiﬁcation of chlorogenic acid as active
principle. Unfortunately, the whole work was published without
anyexperimental results concerning thepharmacological part. This
rather unclear situation together with the fact that we recently
were able to isolate six new iridoid glycosides from the leaves of
Sambucus ebulus L. (Pieri et al., 2009) with unknown pharmacolog-
ical properties prompted us to perform an activity-guided isolation
of an ethanolic extract of the leaves of Sambucus ebulus L. in order
to identify the anti-inﬂammatory principal. Since there are sev-
eral pathways involved in inﬂammatory processes, e.g. arachidonic
acid pathway via COX1/2 and LOX subtypes, NFB pathway; PPARs,
LXR and many others, we had to decide which model would sup-
Open access under CC BY-NC-ND license. port the current state of investigations. With respect to the work
of Yesilada et al. (1997) we decided to establish a very general
model of inhibition of the TNF induced expression of vascular cell
adhesion molecule 1 (VCAM-1) on the surface of human umbilical
vein endothelial cells (HUVECs). Increased expression of VCAM-1 is
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ssociated with a variety of chronic inﬂammatory conditions, mak-
ng its expression and function a target for therapeutic intervention
Besemer et al., 2005). Besides the feasibility of high throughput
creening this assay allows to monitor several targets affected by
NF, e.g. NFB activation are monitored at once (Nakanishi and
oi, 2005). The disadvantage of this model is the fact that you need
nother assay for controlling cell viability, since a reduced number
f cells leads also to a reduction of detectable VCAM-1.
. Materials and methods
.1. General
All reagents used were of purissimum or analytical grade and
erepurchased fromSigma–Aldrich (Vienna,Austria) unless speci-
edotherwise.HPLCsolventswereof gradient gradeandpurchased
rom Sigma–Aldrich aswell.Waterwas produced by reverse osmo-
is followed by distillation. Pure grade solvents were distilled prior
o use. Ursolic acid purchased from Sigma was of 98.5% purity.
.2. Cell isolation and culture
Human umbilical vein endothelial cells (HUVECs) were iso-
ated from umbilical cords (kindly donated by the Gynaecology
nd Obstetrics Department, Innsbruck Medical University) by
nzymatic detachment using collagenase, as previously described
Bernhard et al., 2003). Cells were routinely passaged in 0.2%
elatine-coated (Sigma, Steinheim, Germany) polysterene culture
asks (Becton Dickinson, Meylan Cedex, France) in Endothelial Cell
asalMedium(CC-3121, BioWhittaker, Inc.,Walkersville,MD,USA)
upplemented with EGM SingleQuots Supplements and growth
actors (CC-4133, BioWhittaker, Inc.) in a humidiﬁed atmosphere
ontaining 5% CO2. Fetal bovine serum (FBS; 2%)was routinely used
or cell culturing and experiments. The isolation and analysis of
uman umbilical cord ECs were approved by the Ethics Committee
f the Innsbruck Medical University.
.3. Quantiﬁcation of endothelial surface vascular cell adhesion
olecule 1 (VCAM-1) expression
To analyze and quantify TNF-induced VCAM-1 expression on
he surface of HUVECs, 10,000 HUVECs were seeded into each
ell of a 96-well plate and allowed to adhere overnight. Follow-
ng replacement ofmediumwith 200L of freshmedium, different
ilutions of plant extracts or solvents (as controls) were added to
hewells. After an incubationperiodof 30min, human recombinant
NF (Peprotech (Eubio), 300-01A)was added to thewells at a ﬁnal
oncentration of 100ng/mL. After incubation for 15h, supernatants
erediscarded, cellswerewashedﬁve times in ice coldPBS, and the
6-well plates were put on ice. Following blocking of non-speciﬁc
indings sites with 1% BSA in PBS for 60min, mouse anti-human
D106/VCAM-1 antibody (Neomarkers, MS-1101-P, ﬁnal concen-
ration 0.2g/mL in PBS, 1% BSA) was added to the wells or isotype
ontrol (Mouse IgG1, Dako, X0931, ﬁnal concentration 0.2g/mL
n PBS, 1% BSA) and incubated for 30min on ice on a horizontal
haker. Following washing of cells ﬁve times in ice cold PBS, cells
ere incubated with HRP labelled secondary antibodies (goat anti-
ouse HRP, Dako, P0447, ﬁnal concentration 1g/mL in PBS, 1%
SA) for 30min on ice. After another washing step (ﬁve times with
ce cold PBS), 0.32mg/mL of ABTS (Roche) in ABTS buffer (512mg
aBO3-trihydrate, 8.799g citric acid 1-hydrate, and Di-NaHPO4-
ihydrate 11.214g/l (pH 4.4)) was added to the wells and allowed
o develop for 45min in the dark. OD was determined at 405nm. At
east three dilutions per extract/fraction were tested in four paral-
els, and each experiment was repeated three to ﬁve times. Positive
ontrol: parthenolide (Sigma–Aldrich) 10M, VCAM-1 expressionrmacology 133 (2011) 704–709 705
(% of control): 5.35±0.38%. All data were veriﬁed by FACS-based
quantiﬁcation of VCAM-1 (data not shown).
2.4. Quantiﬁcation of endothelial surface inter cellular adhesion
molecule 1 (ICAM-1) expression
The protocol for the quantiﬁcation of surface ICAM-1 on
endothelial cells was identical to the protocol for VCAM-1 detec-
tion (see above). Antibodies used were: anti-mouse anti-human
CD54/ICAM-1 antibody (Neomarkers, MS-1094-S, 1:15 in PBS, 1%
BSA), isotype control (Mouse IgG1, Dako, X0931, ﬁnal concentra-
tion 0.2g/mL in PBS, 1% BSA), HRP-labelled secondary antibodies
(Goat anti-Mouse HRP, Dako, P0447, ﬁnal concentration 1g/mL
in PBS, 1% BSA). Positive control: parthenolide (Sigma–Aldrich)
10M, ICAM-1 expression (% of control): 38.89±16.6%.
2.5. Analysis of the number of viable cells
The number of viable cells in the cultures was determined by
the XTT assay (Biomol, Hamburg, Germany) according to the man-
ufacturer’s instructions.
2.6. Plant material
Leaves of Sambucus ebulus L. were collected in Gaaden
(Carinthia/Austria) from an uncultivated site in September 2003.
A herbarium specimen (CS-09200301) is stored at the Institute
of Pharmacy/Pharmacognosy, University of Innsbruck. The fresh
leaves (830g)were air dried at room temperature in a shaded room
for 14days. The presented phytochemical work was carried out
from October 2003 to September 2005.
2.7. Chromatography and NMR analyses
High-speed counter-current chromatography (=HSCCC): P.C.
Inc. (Potomac; MD, USA; model: HSCCC multilayer (triple) coil, ser.
690)HSCCC instrumentwithGilson 302/803 C pump systemmodel
302 (Villiers-la-Bel, France). LC for quantiﬁcation: LC-parameter:
HP 1050 system (Agilent, Waldbronn, Germany) equipped with
auto sampler, DAD and column thermostat; stationary phase: Phe-
nomenex Luna 3 C8 100A (150mm×3.0mm) with Synergy Polar
RP 80A guard column; mobile phase: solvent A: H2O with 0.02 tri-
ﬂuor acetic acid (v/v); solvent B: acetonitrile; DAD: 205nm, temp.:
35.0 ◦C; injection volume: 5L; ﬂow: 0.2mL/min; composition
during run: start: 60%A; 10min: 30%A; 40min: 2% A; 55min: stop;
post time: 15min. LC–MS: LC-parameter: HP 1100 system (Agi-
lent, Waldbronn, Germany) equipped with auto sampler, DAD and
column thermostat; stationary phase: Phenomenex Synergy Polar
RP 80A (150mm×4.6mm) with identical guard column; mobile
phase: solvent A: H2O with 0.9% formic acid, 0.1% acetic acid (v/v);
solvent B: acetonitrile +methanol (v/v, 1 +1); DAD: 250nm, temp.:
40 ◦C; injection volume: 10L; ﬂow: 1.0mL/min; composition dur-
ing run: start: 50% A; 20min: 42% A; 21min: 28% A; 40min: 4% A;
45min: stop; post time: 10min. MS-parameters: Esquire 3000plus
(Bruker Daltonics, Bremen, Germany); split: 1:5; ESI, alternating
mode; spray voltage: −4.5 kV, 350 ◦C; dry gas: 10.00 L/min; nebu-
lizer 40psi; full scan mode: m/z 100–1500. TLC: silica gel 60 F254
plates (VWR Darmstadt, Germany) mobile phase: toluene+ethyl
acetate (1 +1; v/v), chemical derivatization with vanillin-sulfuric
acid reagent. NMR: 1D- and 2D-experiments were measured on
a Bruker DRX 300 (Bruker Biospin Rheinstetten, Germany) oper-
ating at 300.13MHz (1H) and 75.47MHz (13C) at 300K (chemical
shifts ı in ppm, coupling constants J in Hz); NMR solvent: DMSO-
d6 with 0.03% TMS (Eurisotop Gif-Sur-Yvette, France), which was
used as internal standard. Melting point (m.p.): Koﬂer hot-stage
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extraction. Activity of the petroleum ether fraction was compara-
ble to that of the starting ethanol extract, whereas the diethyl ether
fraction caused an even more pronounced reduction of VCAM-1
expression (90.7%). The more polar fractions had little effects or
were almost inactive (ethyl acetate: 39.4%,n-butanol: 15.2%,water:06 S. Schwaiger et al. / Journal of Eth
icroscope; uncorr. Optical rotation: Perkin-Elmer 341 polarime-
er (Wellesley, MA, USA) at 25 ◦C.
.8. Extraction and separation
Extraction was carried out with 570g of the milled air-dried
eaves, which were macerated with 2.5 L EtOH96% for 24h at room
emperature. The mixture was sonicated for 10min and ﬁltered.
he obtained solution was evaporated to dryness using a rotava-
or at 25 ◦C. This procedure was repeated eight times with fresh
olvent each time and collectively yielded 116.25g crude extract.
he initial separation was performed by means of liquid–liquid
xtraction; 95.23g of the crude extract were suspended in 1.0 L
ater and transferred into the separatory funnel. The suspen-
ion was extracted six times with 500mL of solvents of different
olarity starting with petroleum ether, diethyl ether, ethyl acetate
nd ﬁnally water saturated n-butanol. The obtained fractions were
vaporated to dryness yielding 18.94g petroleum ether, 20.45g
iethyl ether, 7.69 g ethyl acetate, 18.24g n-butanol and 35.10g
ater fraction (highly hygroscopic). Since the activity was concen-
rated in the obtained diethyl ether fraction, 19.0 g of the fraction
ere subjected to silica gel column chromatography using 230g
erck silica gel 60 (0.040–0.063mm, 230–400 mesh) as stationary
hase and a gradient of petroleum ether and increasing amounts
f ethyl acetate as mobile phase. The eluate was monitored by TLC
nd combined to eight fractions (SE-D 1 to SE-D 8). The activitywas
ocated in fractions SED 4, 5 and 6. Due to the higher amount and
urity of fraction SE-D 4 (2.55g) compared to the total amount of
E-D 5 and 6 (1.50g), the further separation steps were carried out
ith fraction SE-D 4. For further enrichment, SE-D 4 was divided
n a dichloromethane (=DCM)-soluble and a DCM-insoluble part.
or this purpose, 2.20 g of SE-D 4 were suspended in 10.0mL DCM
nd sonicated for 5min. The mixture was ﬁltered over a sintered
late funnel (porosity nr. 4). The same procedure was repeated
our times yielding two fractions: SE-Ak-f-DCM-soluble (0.48g)
nd SE-Ak-f-DCM-insoluble (1.71g). The further separation of the
ctive fraction SE-Ak-f-DCM-insoluble was performed by means
f liquid–liquid extraction using 1.64g of SE-Ak-f-DCM-insoluble
nd 900mL of a solvent mixture of petroleum ether, ethyl acetate,
cetonitrile and tertiary butyl-methyl ether (10+1+5+2, all v/v).
he evaporated upper layer yielded 1.10g, the lower layer afforded
ielded 0.54g (SE-Ak-g). The residue of the lower layer was further
uriﬁed by means of HSCCC using a solvent mixture of petroleum
ther, ethyl acetate, acetonitrile and tertiary butyl-methyl ether
10+1+5+2, all v/v) using the upper layer as mobile phase. The
ample (458.12mg of SE-Ak-g) was suspended in 10.0mL of the
owerphase and5.0mLof theupper phase andﬁlteredbefore injec-
ion yielding an insoluble part of 129.80mg. The used coil had a
olume of 325mL and was used in the tail-to-head-modus with a
otation of 800 rpm. The used ﬂow rate was 1.00mL/min, fractions
ere collected in portions of 5mL. Although the separation tech-
ique enabled a good separation of the compounds, which were
ombined to three fractions (SE-Ak-h 1–3), the activity remained
n the insoluble part (SE-Ak-h RS). Since the residue (SE-Ak-h RS)
ormed pale yellow crystals, the insoluble part was subjected to
rystallization with a mixture of acetonitrile and tetrahydrofuran
v/v; 1 +1). The ﬁrst crystallization afforded 67.7mg of off-white
latelets, which were crystallized a second time from the same
olvent mixture yielding 47.3mg of white platelets.
.9. Structure elucidation of the active principleLC–MS analysis of the crystallized residue afforded in positive
ode m/z of 439.3; 457.3 and 479.4 corresponding to the pseudo-
olecular ions of [M−H2O]+, [M+1]+ and [M+Na]+ as well as a m/z
f 455.2 in negative mode corresponding to [M−1]− suggesting armacology 133 (2011) 704–709
molecular weight of 456g/mol. The 1D and 2D NMR-analysis of
20.0mg of the obtained compound enabled the identiﬁcation of
the isolated compound as ursolic acid (Tundis et al., 2002) with
85% purity.
2.10. Determination of ursolic acid concentration in the diethyl
ether fraction
Quantiﬁcation of the ursolic acid concentration was carried out
by a HPLC-DAD method using the method of external standard
with a calibration curve of y=6446x+98.509 (R2 =0.9999). For this
purpose, the commercial ursolic acid was dissolved in three con-
centrations (5mM, 0.5mMand 0.25mM) in DMSO and analyzed by
HPLC in triplicate. Determination of the ursolic acid concentration
in DMSO solution in the obtained diethyl ether fraction (10mg/mL)
afforded a content of 14.79±0.03% (w/w).
3. Results
3.1. Activity-guided isolation
Results of the activity-guided fractionation are summarized in
Fig. 1. Activity was evaluated monitoring the reduction of TNF
induced VCAM-1 expression of HUVECs. A crude ethanol leave
extract which reduced VCAM-1 expression by 74.5% (c=33g/mL)
compared to control was used as starting material.
First, this extract was divided in ﬁve fractions by liquid–liquidFig. 1. Activity guided isolation schema. Extract of the leaves of Sambucus ebulus
L. was subjected to activity-guided fractionation monitoring the reduction of TNF
induced VCAM-1 expression of HUVECs. PE =petroleum ether, DEE=diethyl ether,
EtOAc=ethyl acetate.
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Fig. 3. Comparison of the activity of isolate and commercially available ursolic acid
(UA). The upper diagram shows a comparison of the isolated vs. the commercial
product on the basis of inhibition of VCAM-1 expression. To conﬁrm speciﬁcity
an isotype control was included in the experiments. Mean values of a represen-
tative experiment performed in quadruplicate± S.D. are shown. Positive control:
parthenolide 10M, VCAM-1 expression OD 405nm: 0.114±0.008. The lower dia-
gramshows an analysis of cytotoxicity/cell viability by theXTT assay. Data represent
(Ramachandran and Prasad, 2008), anti-inﬂammatory as well asFig. 2. Chemical structure of ursolic acid.
3.9%). Silica gel column chromatography of the diethyl ether frac-
ionyieldedeight fractions. Fraction4 (SED4),whichshowedpotent
ctivity, was separated into two fractions according to their sol-
bility in DCM. The active DCM insoluble part was subjected to
iquid/liquid partitioning followed by HSCCC. Of the resulting four
ractions fraction 4 (SHE RS) turned out to contain the active prin-
iple. Final crystallization from CH3CN/THF yielded ursolic acid as
ajor constituent. Its structure (Fig. 2) was conﬁrmed by mass
pectrometry and 1 and 2DNMR spectroscopy and is reported form
his source the ﬁrst time.
.2. Biological characteristics of the isolate and comparison with
ommercially available ursolic acid
Ursolic acid isolated from the leaves of Sambucus ebulus L.
purity 85%) reduced TNF induced VCAM-1 expression of HUVECs
nadosedependentmannerwith an IC50 value12.5M. In compar-
son commercial ursolic acid (purity >98.5%) showed an IC50 value
f 6.25M (Fig. 2; positive control: parthenolide 10M, VCAM-1%
f control: 5.35±0.38%). Besides inhibition of VCAM-1 expression
uriﬁed and commercial ursolic acid signiﬁcantly reduced viability
f both endothelial and smooth muscle cells (SMCs). IC50 values
f puriﬁed and commercial ursolic acid determined by the XTT
ssay (Fig. 3) were 22M and 11.5M, respectively. Viability data
or SMCs were almost identical with those for ECs and are there-
ore not shown. Reason for the differences between ursolic acid
e isolated from plant material and the commercially available
ompound may be the different grade of purity (85% compared to
98.5%). These ﬁndings prompted us to use commercial ursolic acid
or all subsequent experiments.
.3. Ursolic acid inhibits TNF˛-mediated ICAM-1 surface
xpression
Since exposure of HUVECs to TNF is known to cause not
nly expression of VCAM-1 but also expression of other adhe-
ion molecules, we tested whether ursolic acid is antagonizing also
CAM-1 expression. Fig. 4 shows the outcomes: ursolic acid inhibits
NF stimulated surface expression of ICAM-1 on endothelial cells
n a dose dependentmanner (IC50 value between3.13 and6.25M;
ositive control: parthenolide 10M, ICAM-1 expression (% of con-
rol): 38.89±16.6%). In the absence of TNF ursolic acid does not
as any effect on ICAM-1 expression.meanvalues of a representative experiment performed in triplicate± S.D. Cellswere
exposed to the compounds for 24h (compounds were added 30min prior to TNF
addition).
4. Discussion
Extracts of roots and leaves of Sambucus ebulus L. have been
used in traditional medicine to treat health problems associated
with inﬂammation such as inﬂammatory joint diseases, rheumatic
pain and sore throat. Several studies have conﬁrmed the anti-
inﬂammatory potential of dwarf elder extracts, but the nature of
the active principle remained unsolved. In the course of this project
an activity guided isolation approach resulted in identiﬁcation of
ursolic acid as active principal for the inhibitory effect of dwarf
elder leave extracts against TNF induced HUVEC surface expres-
sionofVCAM-1. Interestingly, noneof the recently identiﬁed iridoid
derivatives (Pieri et al., 2009)was involved in the observed activity.
Ursolic acid is a widespread pentacyclic tripernoid and has pre-
viously been isolated from a number of different plants species, e.g.
rosemary and basil. Recent reports have ascribed to ursolic acid
chemo-preventive properties (Lu et al., 2007), cell death-inducing
(Achiwa et al., 2005), anti-mutagenic (Ramos et al., 2008) and anti-
viral activities (Serra et al., 1994), direct anti-oxidative propertiespro-inﬂammatory properties (Ikeda et al., 2008), pro-angiogenic
and antiangiogenic properties (Sohn et al., 1995; Cardenas et al.,
2004), ability to induce differentiation (Lee et al., 1994), and
708 S. Schwaiger et al. / Journal of Ethnopharmacology 133 (2011) 704–709
Fig. 4. Ursolic acid inhibits TNF-mediated ICAM-1 expression of endothelial
cells. To conﬁrm speciﬁcity an isotype control was included in the experiments.
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Fig. 5. Effect of diethyl ether fraction adjusted to the correspondingursolic acid con-ean values of a representative experiment performed in quadruplicate± S.D. are
hown. Positive control: parthenolide 10M, ICAM-1 expression (% of control):
8.89±16.6%.
nti-invasive activities (Cha et al., 1996). Findings that might be
f relevance for an application of ursolic acid in cardiovascular
edicine includevasorelaxant activity (Aguirre-Crespoet al., 2006)
nd an up-regulation of eNOS (Steinkamp-Fenske et al., 2007),
s well as anti-oxidant activity, e.g. inhibition of lipid peroxida-
ion (Balanehru and Nagarajan, 1991). In an insulin-resistant rat
odel of genetic hypertension, ursolic acid was further shown to
ave antihypertensive, heart rate-lowering, anti-hyperlipidemic,
nd anti-hyperglycemic effects (Somova et al., 2003).
Despite a few reports on pro-inﬂammatory effects, which may
e based on speciﬁc cellular and tissue environments, ursolic
cid is generally considered to act as an anti-inﬂammatory agent,
.g. by inhibition of COX-2 transcription (Subbaramaiah et al.,
000), release of macrophage migration inhibitory factor (Ikeda
t al., 2005), inhibition of IL-8 secretion (Thuong et al., 2005), and
ownregulation of enzymes required for permeation of lympho-
ytes/monocytes through basal lamina such asMMP-9 and elastase
Cha et al., 1996). In general, a number of effects of ursolic acid on
ells in culture were ascribed to an interaction with cellular sig-
alling at or around NFB activation and/or activity. However – to
ur knowledge – up to now only one report suggested a precise
ite of interaction of ursolic acid with NFB, namely inhibition of
B-kinase and phosphorylation of p65 (Shishodia et al., 2003).
Our ﬁndings indicate that ursolic acid is able to inhibit TNF-
timulated expression of vascular cell adhesion molecules as well
s the expressionof inter cellular adhesionmolecules.While reduc-
ion of VCAM-1 corroborates the use of dwarf elder extracts for
he therapy of chronically inﬂammatory processes, reduction of
he TNF-stimulated expression of ICAM-1 might at least partially
xplain the (traditional) useofdifferent Sambucus species, e.g. ﬂow-
rs of S. nigra L. containing 0.72% ursolic acid according to Richter
nd Wilhun (1977) for the treatment of common cold. ICAM-1
erves as a crucial target-docking molecule on epithelial cells for
0% of human rhinovirus (HRV) serotypes, which are responsible
or up to 65% of common colds (Whiteman and Spiteri, 2008).In agreement with literature data, our in vitro analyses showed
hat ursolic acid has a profound cell death-inducing activity. Inter-
stingly, as constituent of an extract the toxicity of ursolic acid
eems to be diminished. This was quite evident when compar-centration on VCAM-1 expression (light bars) and cell viability (dark bars). Shown
are representative experiments performed in quadruplicates± S.D. Positive control:
parthenolide (10M); VCAM-1 expression (% of control): 5.35±0.38%.
ing the dwarf elder diethyl ether fraction (DEE-fr. containing
14.79±0.03% (w/w) ursolic acid) with the pure compound urso-
lic acid: despite its slightly lower VCAM-1 expression-repressing
activity (Fig. 5; IC50 of 20M compared to 5–10M ursolic acid) it
is signiﬁcantly less toxic as suggested by the content of ursolic acid
in the extract demonstrated a clearly more pronounced reduction
of toxicity (IC50 >108M compared to 10–20M ursolic acid).
One reason for the observed alleviation of side effects might
be related to an induction of phase II detoxiﬁcation enzymes.
Since also chlorophyll, which is present in a high amount in the
diethyl ether fraction, is able to induce phase II enzymes like heme
oxygenase-1 (=HO-1) and quinone oxidoreductase-1 (=NQO1)
(Zhang et al., 2008) it can be assumed that the observed effect is
a result of an interaction between ursolic acid and present chloro-
phyll derivatives. The veriﬁcation of this hypothesis is part of an
ongoing research project.
5. Conclusions
Results from this study clearly showed that extracts and frac-
tions of the leaves of Sambucus ebuluss L. are able to inhibit
TNF-stimulated expression of VCAM-1 and ICAM-1 in HUVECs.
The responsible principal for this effect was identiﬁed as ursolic
acid. Our ﬁndings support the traditional use of extracts and prepa-
rations of Sambucus ebulus L., rich in ursolic acid, for the treatment
of chronically inﬂammatory processes.
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